ILC Therapeutics is Drug Discovery in United Kingdom that focus on novel peptide therapeutics business. Founded in 2012. They cover business area such as developer novel peptide therapeutic, ARDS, oncology, Psoriasis, Atopic Dermatitis, interferon medicine, Hybrid Interferons, feature, natural interferon subtype, one new hybrid Interferon molecule, enhance efficacy, high-value therapeutic area, healthcare provider, patient outcome.
2012
( 12 years old in 2024 )
Novel Peptide Therapeutics
-
Biocity
Bo'ness Road, Newhouse
Lanarkshire ML1 5UH
Scotland, United Kingdom
Private
developer novel peptide therapeuticARDSoncologyPsoriasisAtopic Dermatitisinterferon medicineHybrid Interferonsfeaturenatural interferon subtypeone new hybrid Interferon moleculeenhance efficacyhigh-value therapeutic areahealthcare providerpatient outcome
* We use standard office opening hours in near ILC Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
ILC Therapeutics is Drug Discovery business from United Kingdom that founded in 2012 (12 years old in 2024), ILC Therapeutics business is focusing on Novel Peptide Therapeutics.
ILC Therapeutics headquarter office and corporate office address is located in Biocity Bo'ness Road, Newhouse Lanarkshire ML1 5UH Scotland, United Kingdom.
ILC Therapeutics was founded in United Kingdom.
In 2024, ILC Therapeutics is currently focus on novel peptide therapeutics sector.
Above is snippet of Google Trends for "novel peptide therapeutics" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with ILC Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
